Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07491029

AI-based Customized tDCS for Finger Motor Recovery After Subacute Stroke

The goal of this clinical study is to evaluate whether AI-based customized transcranial direct current stimulation (tDCS) using MR images is more effective than sham stimulation in improving finger motor function in patients with finger paralysis caused by subacute stroke. The main questions it aims to answer are:

* Does AI-based customized tDCS improve finger motor function compared with sham stimulation? * What medical problems or adverse events occur when participants receive AI-based customized tDCS?

Researchers will compare AI-based customized tDCS with sham stimulation (a look-alike stimulation that delivers no electrical current) to determine whether the intervention improves finger motor recovery in patients with subacute stroke.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

19 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Severance Hospital

Seoul, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Participants must meet all of the following criteria to be eligible for this clinical trial:

  • Adults aged 19 years or older
  • Patients with stroke confirmed by brain imaging
  • Subacute stroke patients within 2 weeks to 3 months after stroke onset
  • Patients with unilateral upper-extremity paralysis
  • Upper-extremity Fugl-Meyer Assessment (FMA-UE, maximum score 66) score between 20 and 56
  • Participants who voluntarily provide written informed consent after receiving and understanding the study procedures and requirements

Exclusion criteria

Participants will be excluded if they meet any of the following criteria:

  • History of a condition affecting the function of the paralyzed arm
  • Inability to follow instructions or complete the study due to cognitive impairment or aphasia
  • Evidence of delirium, confusion, or other disorders of consciousness
  • Presence of uncontrolled medical or surgical conditions
  • Severe neurological disorders associated with major psychiatric conditions (e.g., major depressive disorder, schizophrenia, bipolar disorder, or dementia)
  • History of uncontrolled epilepsy (seizure disorder)
  • Contraindications to transcranial direct current stimulation (tDCS), including:
  • Scalp disease or metal materials at the electrode attachment site
  • Presence of a cardiac pacemaker or cochlear implant
  • Medical contraindications to MRI examination
  • Pregnant or breastfeeding women, or those planning pregnancy during the study period
  • Use of a stimulation device similar to the investigational device or participation in a related clinical study within the past 1 year
  • Individuals judged by the investigator to be medically or ethically unsuitable for participation in this clinical study

Treatment and study plan

AI-based Customized transcranial Direct Current Stimulation

Device

Transcranial direct current stimulation (2 mA for 30 minutes) will be delivered using electrode positions optimized by an AI-based simulation based on each participant's MR images to target the motor cortex.

Other names: NEUROPHET tES LAB, NEUROPHET innk01-DW

Sham Transcranial Direct Current Stimulation

Device

Transcranial direct current stimulation (0 mA for 30 minutes) will be delivered using electrode positions optimized by an AI-based simulation based on each participant's MR images.

Other names: NEUROPHET tES LAB, NEUROPHET innk01-DW

Primary outcomes

  1. Fugl-Meyer Function Test

    Time frame: Baseline, At 2 weeks from baseline

    The Fugl-Meyer Assessment (FMA) is a validated clinical scale used to evaluate sensorimotor recovery in patients with post-stroke hemiplegia based on Brunnstrom stages of motor recovery. Each item is scored on a 3-point scale (0 = cannot perform, 1 = performs partially, 2 = performs fully).

    In this study, the upper-extremity FMA will be used. The assessment includes items evaluating the shoulder, elbow, forearm, wrist, hand (fingers), coordination/speed, sensation, passive joint motion, and joint pain during passive movement, with a total score ranging from 0 to 126 points.

Secondary outcomes

  1. Fugl-Meyer Function Test

    Time frame: Baseline, At 1, 3, 4, 14 weeks from baseline

    The Fugl-Meyer Assessment (FMA) is a validated clinical scale used to evaluate sensorimotor recovery in patients with post-stroke hemiplegia based on Brunnstrom stages of motor recovery. Each item is scored on a 3-point scale (0 = cannot perform, 1 = performs partially, 2 = performs fully).

    In this study, the upper-extremity FMA will be used. The assessment includes items evaluating the shoulder, elbow, forearm, wrist, hand (fingers), coordination/speed, sensation, passive joint motion, and joint pain during passive movement, with a total score ranging from 0 to 126 points. Additional analyses will include comparisons between dominant and non-dominant hands.

  2. Wolf Motor Function Test

    Time frame: Baseline, At 1, 2, 3, 4, 14 weeks from baseline

    The Wolf Motor Function Test (WMFT) is a validated assessment used to evaluate upper-extremity motor function in individuals with mild to moderate impairment following stroke or traumatic brain injury. The test is based on direct observation of the participant's performance.

    The assessment consists of 19 tasks evaluating upper-extremity function. For items 1-15, performance time and functional ability are measured. Functional ability is rated on a 6-point scale from 0 (does not attempt the task) to 5 (normal performance), and task completion time is recorded with a maximum limit of 120 seconds per task.

    Two additional items assess upper-extremity strength and grip strength. Additional analyses will include comparisons between dominant and non-dominant hands.

  3. Box and Blocks Test

    Time frame: Baseline, At 1, 2, 3, 4, 14 weeks from baseline

    The Box and Blocks Test (BBT) is a standardized assessment used to evaluate upper-extremity gross manual dexterity and coordination. During the test, participants move wooden blocks one at a time from one compartment of a box to another over a partition using one hand.

    The test is performed for 1 minute for each hand. The total number of blocks successfully transferred within the time limit is recorded as the score. If more than one block is moved at the same time, the additional blocks are not counted. Additional analyses will include comparisons between dominant and non-dominant hands.

  4. Korean version of Modified Barthel Index (K-MBI)

    Time frame: Baseline, At 1, 2, 3, 4, 14 weeks from baseline

    The Modified Barthel Index (MBI) is a standardized assessment used to evaluate activities of daily living (ADL). The scale consists of 10 items assessing functional independence, including personal hygiene, bathing, feeding, toileting, stair climbing, dressing, bowel control, bladder control, ambulation (or wheelchair use), and transfers between a bed and chair.

    Each item is scored according to the level of assistance required, with a total score ranging from 0 to 100. Lower scores indicate greater dependence in daily activities, while scores between 91 and 99 indicate minimal dependence. The MBI is widely used due to its reliability, sensitivity, and practicality for evaluating functional recovery and mobility in rehabilitation. Additional analyses will include comparisons between dominant and non-dominant hands.

  5. Grip Strength

    Time frame: Baseline, At 1, 2, 3, 4, 14 weeks from baseline

    Grip strength is measured to assess hand muscle strength of the affected and unaffected upper extremity. Participants squeeze a hand dynamometer with maximum effort, and the measured force is recorded as the grip strength value. Additional analyses will include comparisons between dominant and non-dominant hands.

  6. EuroQol 5-Dimension 5-Level (EQ-5D-5L)

    Time frame: Baseline, At 2, 14 weeks from baseline

    Quality of life (QoL) will be assessed using the EQ-5D-5L, a standardized self-reported questionnaire. The instrument evaluates five dimensions of health status: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.

    Each dimension has five levels ranging from "no problems" (Level 1) to "extreme problems or inability to perform" (Level 5). Participants select the level that best describes their current health status, generating a health profile. The EQ-5D-5L will be used to compare changes in quality of life between the intervention and sham groups.

  7. Motor-Evoked Potential (MEP)

    Time frame: Baseline, At 2 weeks from baseline

    The cortical excitability of the area corresponding to the swallowing movement will be assessed by changes in the amplitude and latency of the MEPs by using transcranial magnetic stimulation (TMS).

Study contacts

Contact information is provided by the study sponsor or research team.

Soo Young Whang

CONTACT

[email protected]

TaeYeong Kim

CONTACT

[email protected]

827051678882

Sponsors and collaborators

Lead sponsor

NEUROPHET

Industry

Collaborators

  • Asan Medical Center
  • Bucheon St. Mary's Hospital
  • National Health Insurance Service Ilsan Hospital
  • National Rehabilitation Center, Seoul, Korea
  • Samsung Medical Center
  • Severance Hospital

Registry information

Official study title

A Multi-center, Randomized, Double-blind, Prospective, Superiority Clinical Trial to Evaluate the Safety and Effectiveness of Artificial Intelligence-based Customized Transcranial Direct Current Stimulation Using MR Images for Improving Finger Motor Function in Patients With Finger Paralysis Due to Subacute Stroke

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Mar 24, 2026
Registry last updated
Mar 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.